Climb Bio's ITP Drug Shows Durable Platelet Gains in Encouraging Phase 1b Data
Summary
Climb Bio announced encouraging Phase 1b data for its intravenous formulation of budoprutug in patients with primary ITP. The 250 mg cohort demonstrated strong B-cell depletion and a mean platelet increase of 111,000/µL at Week 24, with 4 of 6 patients achieving durable platelet responses. The drug was well-tolerated with no serious adverse events. This positive early-stage data for a lead asset builds on the FDA Fast Track designation received in April and positive data for the subcutaneous formulation in May. Validating the drug's potential in ITP is critical for the company's pipeline and future development.
At the time of this announcement, CLYM was trading at $10.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $618.4M. The 52-week trading range was $1.16 to $12.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.